Reports Q3 revenue $211.0M, consensus $175.52M. Cash, cash equivalents, and marketable securities were $1.687B as of September 30, compared to $1.139B as of December 31, 2024. “We achieved an outstanding quarter, highlighted by the strong start to the global Sephience launch,” said Matthew B. Klein, CEO. “The broad initial uptake supports the potential of Sephience to become the standard of care for all individuals with PKU, as well as the foundational product for PTC’s sustained growth and success.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Truist sees no read-throughs to PTC, Wave Life from uniQure news
- PTC Therapeutics price target raised to $77 from $63 at Jefferies
- PTCT Upcoming Earnings Report: What to Expect?
- PTC Therapeutics price target raised to $87 from $76 at BofA
- Optimistic Buy Rating for PTC Therapeutics Driven by Strong Demand and Promising Sales Projections for Sephience